Samarth Kulkarni is Chairman and Chief Executive Officer of CRISPR Therapeutics AG (CRSP). The company reported total compensation of $7,678,477 for fiscal year 2025.
| Salary | $768,622 |
|---|---|
| Bonus | $0 |
| Stock awards | $3,474,900 |
| Option awards | $2,768,862 |
| Non-equity incentive plan | $659,093 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $7,000 |
| Total | $7,678,477 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure CRISPR Therapeutics AG filed April 21, 2026, accession 0001193125-26-165158.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chairman and Chief Executive Officer | $768,622 | $0 | $3,474,900 | $2,768,862 | $659,093 | $0 | $7,000 | $7,678,477 |
| FY2024 | Chairman and Chief Executive Officer | $746,235 | — | $25,344,025 | $6,436,600 | $637,285 | — | $11,481 | $33,175,626 |
| FY2023 | Chairman and Chief Executive Officer | $724,500 | — | $4,435,690 | $6,531,705 | $618,723 | — | $11,578 | $12,322,196 |
Totals as disclosed in each year's own compensation disclosure for CRISPR Therapeutics AG.
| Peer-group chief executive median | $10,957,451 |
|---|---|
| Difference from that median | $-3,278,974 |
| Percentile within the disclosed peer group | 29th |
| Peers with a disclosed figure | 17 |
Medians and percentiles are computed across the peer group CRISPR Therapeutics AG discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Samarth Kulkarni this page | Chairman and Chief Executive Officer | $7,678,477 |
| Naimish Patel | Chief Medical Officer | $4,309,317 |
| Julianne Bruno | Former Chief Operating Officer | $3,657,660 |
| Raju Prasad | Chief Financial Officer | $3,586,594 |
| James Kasinger | General Counsel and Secretary | $2,861,814 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full CRISPR Therapeutics AG compensation brief.
Samarth Kulkarni's compensation sits inside CRISPR Therapeutics AG's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.